ProQR Therapeutics (NASDAQ:PRQR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Saturday.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
Several other analysts also recently issued reports on the company. Chardan Capital reiterated a “neutral” rating on shares of ProQR Therapeutics in a research note on Tuesday. ValuEngine downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Leerink Swann reiterated an “outperform” rating and set a $12.00 price target (up previously from $10.00) on shares of ProQR Therapeutics in a research note on Tuesday, September 26th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of ProQR Therapeutics in a research note on Tuesday, September 26th. Finally, JMP Securities increased their target price on ProQR Therapeutics from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $18.88.
ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.03. research analysts expect that ProQR Therapeutics will post -2.06 earnings per share for the current year.
A number of large investors have recently made changes to their positions in the stock. Nine Chapters Capital Management LLC bought a new stake in ProQR Therapeutics during the 3rd quarter valued at approximately $133,000. Wells Fargo & Company MN boosted its stake in ProQR Therapeutics by 212.6% during the 3rd quarter. Wells Fargo & Company MN now owns 43,226 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 29,400 shares during the period. Redmile Group LLC boosted its stake in ProQR Therapeutics by 2.8% during the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after purchasing an additional 43,050 shares during the period. Sphera Funds Management LTD. boosted its stake in ProQR Therapeutics by 60.6% during the 3rd quarter. Sphera Funds Management LTD. now owns 530,000 shares of the biopharmaceutical company’s stock valued at $2,571,000 after purchasing an additional 200,000 shares during the period. Finally, Janus Henderson Group PLC bought a new stake in ProQR Therapeutics during the 2nd quarter valued at approximately $2,028,000. Hedge funds and other institutional investors own 31.63% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first reported by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/proqr-therapeutics-prqr-lowered-to-hold-at-zacks-investment-research/1848145.html.
About ProQR Therapeutics
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.